Literature DB >> 20807652

Vascular dermatan sulfate and heparin cofactor II.

Douglas M Tollefsen1.   

Abstract

Heparin cofactor II (HCII) is a plasma protease inhibitor of the serpin family that inactivates thrombin by forming a covalent 1:1 complex. The rate of complex formation increases more than 1000-fold in the presence of dermatan sulfate (DS). Endothelial injury allows circulating HCII to enter the vessel wall, where it binds to DS and presumably becomes activated. Mice that lack HCII develop carotid artery thrombosis more rapidly than wild-type mice after oxidative damage to the endothelium. These mice also have increased arterial neointima formation following mechanical injury and develop more extensive atherosclerotic lesions when made hypercholesterolemic. Similarly, low plasma HCII levels appear to be a risk factor for atherosclerosis and in-stent restenosis in human subjects. These observations suggest that a major function of the HCII-DS system is to regulate the physiologic response to arterial injury.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20807652     DOI: 10.1016/S1877-1173(10)93015-9

Source DB:  PubMed          Journal:  Prog Mol Biol Transl Sci        ISSN: 1877-1173            Impact factor:   3.622


  15 in total

1.  Proteolytic activation transforms heparin cofactor II into a host defense molecule.

Authors:  Martina Kalle; Praveen Papareddy; Gopinath Kasetty; Douglas M Tollefsen; Martin Malmsten; Matthias Mörgelin; Artur Schmidtchen
Journal:  J Immunol       Date:  2013-05-08       Impact factor: 5.422

2.  Sequence analysis and domain motifs in the porcine skin decorin glycosaminoglycan chain.

Authors:  Xue Zhao; Bo Yang; Kemal Solakyildirim; Kemal Solakylidirim; Eun Ji Joo; Toshihiko Toida; Kyohei Higashi; Robert J Linhardt; Lingyun Li
Journal:  J Biol Chem       Date:  2013-02-19       Impact factor: 5.157

3.  Alboserpin, a factor Xa inhibitor from the mosquito vector of yellow fever, binds heparin and membrane phospholipids and exhibits antithrombotic activity.

Authors:  Eric Calvo; Daniella M Mizurini; Anderson Sá-Nunes; José M C Ribeiro; John F Andersen; Ben J Mans; Robson Q Monteiro; Michail Kotsyfakis; Ivo M B Francischetti
Journal:  J Biol Chem       Date:  2011-06-14       Impact factor: 5.157

4.  Paradoxical bleeding and thrombotic episodes of dysprothrombinaemia due to a homozygous Arg382His mutation.

Authors:  Qiulan Ding; Likui Yang; Xiaoqing Zhao; Wenman Wu; Xuefeng Wang; Alireza R Rezaie
Journal:  Thromb Haemost       Date:  2016-12-15       Impact factor: 5.249

5.  Atheroprotective remodelling of vascular dermatan sulphate proteoglycans in response to hypercholesterolaemia in a rat model.

Authors:  Roxana Oberkersch; Francesca Maccari; Alicia I Bravo; Nicola Volpi; Silvina Gazzaniga; Graciela C Calabrese
Journal:  Int J Exp Pathol       Date:  2014-03-07       Impact factor: 1.925

Review 6.  Iduronic acid in chondroitin/dermatan sulfate: biosynthesis and biological function.

Authors:  Anders Malmström; Barbara Bartolini; Martin A Thelin; Benny Pacheco; Marco Maccarana
Journal:  J Histochem Cytochem       Date:  2012-08-16       Impact factor: 2.479

7.  Dermatan sulfate is involved in the tumorigenic properties of esophagus squamous cell carcinoma.

Authors:  Martin A Thelin; Katrin J Svensson; Xiaofeng Shi; Mariam Bagher; Jakob Axelsson; Anna Isinger-Ekstrand; Toin H van Kuppevelt; Jan Johansson; Mef Nilbert; Joseph Zaia; Mattias Belting; Marco Maccarana; Anders Malmström
Journal:  Cancer Res       Date:  2012-02-20       Impact factor: 12.701

Review 8.  Development and use of sulodexide in vascular diseases: implications for treatment.

Authors:  Sergio Coccheri; Ferdinando Mannello
Journal:  Drug Des Devel Ther       Date:  2013-12-24       Impact factor: 4.162

9.  Endocan in cancers: a lesson from a circulating dermatan sulfate proteoglycan.

Authors:  Maryse Delehedde; Lucie Devenyns; Claude-Alain Maurage; Romain R Vivès
Journal:  Int J Cell Biol       Date:  2013-03-28

Review 10.  Biological functions of iduronic acid in chondroitin/dermatan sulfate.

Authors:  Martin A Thelin; Barbara Bartolini; Jakob Axelsson; Renata Gustafsson; Emil Tykesson; Edgar Pera; Åke Oldberg; Marco Maccarana; Anders Malmstrom
Journal:  FEBS J       Date:  2013-03-28       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.